![](https://investorshub.advfn.com/uicon/430424.png?cb=1554906782)
Tuesday, March 13, 2018 3:02:15 PM
publication will be in the Journal of Cancer Research and Clinical Oncology (which is in Germany), and will share how the trial was designed, how patients were screened, how pseudoprogression diagnosis has been complicated by reaction to the vaccine, why the trial was redesigned and expanded, etc., and a lot of numbers from a year ago will appear again but with the caveat that comparison with the average survival of GBM patients has to factor in the screening criteria applied to phase III enrollees that was not applied to the general population of GBM patientswith the control group effectively gone via compassionate crossover the plan now is to compare the survival rate of patients in the phase III with the general population of GBM patients. however doing so presents a problem in that the phase III patients had to meet criteria including proof there was no progression following resection. this was not true of the general population of GBM patients. so comparison between the two would be distorted and would show pseudo success for the phase III patients. (He's overselling bear case through false equivalence)
what this means is that the encouraging numbers advertised at ASCO last year are more likely attributable to careful screening to specific criteria to ensure only the 'best' patients were enrolled in the phase III -- which means the fact some patients are still alive does not necessarily mean the vaccine is working (He's overselling bear case through exaggeration)
sorry to burst your bubble but you are too closed-minded to let that happen anyhow -- Meifud
The fact that he oversells the challenges of matching historical to the Phase three trial is a clue. Also, historically, most trials in this area remove early progressors. Also, the Journal is in Germany, and we know how AF likes to tease about Germany. Nonetheless, I'm not saying the Journal is incorrect, I'm saying we don't know if it's correct.
If the Journal is correct, which is not known, I guess we should also add to the watchlist that German conference Dr. Bosch once presented at, coming up March 19-21. http://itoc-conference.eu Does not look like abstracts were released. Doubt this will be the venue for anything this year.
Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM